Publications

Bimekizumab was superior to placebo in achieving ACR, MDA, and PASI outcomes and had an acceptable safety profile. This meta-analysis also showed that 160mg and 320mg doses of bimekizumab were both superior to placebo in achieving these outcome measures.

This systematic review and meta-analysis by Su, et al. pooled the results of four clinical trials that investigated the efficacy of bimekizumab versus placebo. A comprehensive literature search by August 2023 was performed through PubMed, Embase, Cochrane Controlled Register of Trials, and ClinicalTrials.gov investigating the efficacy or safety data of bimekizumab in the treatment of PsA.